HCMR Re-Imaging Study (NCT07054073)
🩺 Plain-English Summary (8th-Grade Level)
This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properly. It can also affect the heart's electrical system. This study is looking to enroll patients that were previously part of a research project called "HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy." The results of that study are still being reviewed, but they might show that people who had a substance called Gadolinium (MRI contrast or dye) collected in their heart muscle may have a higher risk for heart problems, including sudden cardiac death. This is called "late gadolinium enhancement" (LGE). This study is aiming to do follow-up imaging on those patients to better understand how LGE affects people with HCM.
Who can join: Review the eligibility criteria below.
Location: Northwestern — Evanston, Illinois
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
- None - observational study (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Northwestern — Evanston, Illinois
- Brigham & Women's Hospital — Boston, Massachusetts
- Tufts Medical Center — Medford, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Cleveland Clinic — Cleveland, Ohio
- University of Virginia — Charlottesville, Virginia
- University Hospitals Birmingham NHS Foundation Trust — Birmingham,
- London Chest Hospital — London,
📞 Contact the Study Coordinator
Phone: (434) 924-9553
Email: gms4x@uvahealth.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hypertrophic Cardiomyopathy (HCM)
- Perfusion Abnormalities in Hypertrophic Cardiomyopathy — Charlottesville, Virginia
- COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) — Durham, North Carolina
- Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy — Kansas City, Missouri
- Large Language Models To Improve the Quality of Care of Cardiology Patients — Palo Alto, California
Explore by condition: All Hypertrophic Cardiomyopathy (HCM) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.